UNIVARIATE ANALYSIS OF SURVIVAL | ||||
---|---|---|---|---|
Variable | MST | 1-year survival % | P-value | |
Age Category | ≤ 60 | 16.50 | 53.00% | 0.591 |
 | >60 | 15.75 | 47.86% |  |
Gender | Male | 15.75 | 50.34% | 0.515 |
 | Female | 16.50 | 49.3% |  |
 | 60-70 | 11.75 | 30.30% |  |
Karnofsky PS | 80 | 16.75 | 52.40% | <0.001 |
 | 90-100 | 19.25 | 63.20% |  |
 | 1 | 14.50 | 36.40% | 0.092 |
Histological Grade | 2 | 17.25 | 54.30% | Â |
 | 3 | 14.25 | 44.87% |  |
Lymph node metastasis | No | 13.50 | 28.89% | 0.051 |
 | Yes | 16.75 | 56.65% |  |
Liver metastasis | No | 19.25 | 63.39% | <0.001 |
 | Yes | 12.75 | 37.74% |  |
Lung metastasis | No | 16.25 | 52.24% | 0.185 |
 | Yes | 12.75 | 35.29% |  |
Ovarian metastasis | No | 16.00 | 51.27% | 0.579 |
 | Yes | 17.00 | 47.62% |  |
Bone metastasis | No | 16.25 | 51.18% | 0.282 |
 | Yes | 12.25 | 42.86% |  |
Peritoneal dissemination | No | 16.75 | 54.90% | 0.319 |
 | Yes | 15.00 | 43.70% |  |
Albumin | Normal | 18.00 | 57.66% | 0.002 |
 | Low | 12.75 | 38.30% |  |
CRP | Normal | 18.00 | 56.06% | <0.001 |
 | High | 12.75 | 43.02% |  |
HP | No | 15.50 | 48.59% | 0.35 |
 | Yes | 17.25 | 52.63% |  |
CEA | ≤ 5 | 15.00 | 45.54% | 0.143 |
 | > 5 | 17.00 | 52.83% |  |
CA 19-9 | ≤ 30 | 18.25 | 58.14% | 0.019 |
 | > 30 | 14.50 | 46.21% |  |
CA 72-4 | ≤ 7 | 21.75 | 65.00% | 0.002 |
 | > 7 | 14.75 | 47.46% |  |
 | Low | 22.50 | 73.86% |  |
DNA Index | Medium | 12.75 | 35.20% | <0.001 |
 | High | 09.50 | 23.81% |  |